Akero Therapeutics (AKRO) reported 96-week data in its trial of advanced MASH patients, and there seem really significant ...

a form of non-alcoholic fatty liver disease (NAFLD). In the 182-patient study, patients were treated with one of two doses of the FGF21 mimic or placebo - given as a once-weekly subcutaneous ...

FGF21 is a key metabolic regulator that ... Metabolic dysfunction-associated steatotic liver disease (MASLD), or "fatty liver disease," is the most common chronic liver disease worldwide, an ...